Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is expanding its pipeline and pursuing multiple avenues for potential market entry, including its ALTO-207 drug for TRD which has a higher chance of success and potential for a broader label due to its fixed-dose combination and positive safety profile. The company also plans to initiate a Phase 3 monotherapy trial for ALTO-207 in TRD in 2H27, which could accelerate the path to potential approval. In addition to its strong pipeline, Alto Neuroscience's precision approach to drug development utilizing biomarkers adds potential for higher success rates and can potentially enhance the company's valuation.

Bears say

Alto Neuroscience is facing steep losses with negative GAAP EPS and will require additional financing given their low cash reserves, resulting in an extended cash runway but also requiring a decrease in valuation discount rate. Despite pipeline advancements, more clinical data is needed for clarity on profit potential, leading to a Neutral rating and a lower target price.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.